Terbinafine hydrochloride is under clinical development by Blueberry Therapeutics and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Terbinafine hydrochloride’s likelihood of approval (LoA) and phase transition for Onychomycosis (Tinea Unguium) took place on 29 Aug 2021, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Terbinafine hydrochloride Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Terbinafine hydrochloride overview

Terbinafine hydrochloride (BB-2603) is under development for the treatment of onychomycosis and associated Tinea pedis (athlete’s foot). It is applied through cutaneous and topical route as spray. The drug candidate is a new chemical entity that is developed based on nano-polymer drug delivery technology.

Blueberry Therapeutics overview

Blueberry Therapeutics is a provider of nano medicines for the treatment of dermatological disorders. Its pipeline product portfolio includes BB2603-NCE, developed to treat onychomycosis and associated tinea pedis; BB2312 used for the treatment of Acne diseases, BB0109-NME developed for the treatment of inflammatory bowel disease and BB2702- NME used to treat atopic dermatitis. Blueberry Therapeutics provides peptides, protein and small molecules to treat infections. The company’s drug delivery system based on nanopolymer to self-assembling. It operates through other pharmaceutical companies to develop new drug products. Blueberry Therapeutics is headquartered in Alderley Edge, Cheshire, the UK.

Quick View Terbinafine hydrochloride LOA Data

Report Segments
  • Innovator
Drug Name
  • Terbinafine hydrochloride
Administration Pathway
  • Cutaneous
  • Topical
Therapeutic Areas
  • Infectious Disease
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.